Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient

N. Macesic, D. Langsford, K. Nicholls, P. Hughes, D. J. Gottlieb, L. Clancy, E. Blyth, K. Micklethwaite, B. Withers, S. Majumdar, S. Fleming, J. Sasadeusz

Research output: Contribution to journalArticleOtherpeer-review

33 Citations (Scopus)


Cytomegalovirus (CMV) is a significant cause of morbidity, mortality and graft loss in solid organ transplantation (SOT). Treatment options for ganciclovir-resistant CMV are limited. We describe a case of ganciclovir-resistant CMV disease in a renal transplant recipient manifested by thrombotic microangiopathy-associated glomerulopathy. Adoptive T cell immunotherapy using CMV-specific T cells from a donor bank was used as salvage therapy. This report is a proof-of-concept of the clinical and logistical feasibility of this therapy in SOT recipients.

Original languageEnglish
Pages (from-to)827-832
Number of pages6
JournalAmerican Journal of Transplantation
Issue number3
Publication statusPublished - 1 Mar 2015
Externally publishedYes


  • antibiotic drug resistance
  • antibiotic: antiviral-ganciclovir/valganciclovir
  • clinical research/practice
  • infection and infectious agents
  • infectious disease
  • kidney transplantation/nephrology
  • viral: Cytomegalovirus (CMV)

Cite this